Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City.
紐約，2024 年 3 月 26 日（GLOBE NEWSWIRE）— 智能生物解決方案公司 提供智能、快速、無創檢測解決方案的醫療技術公司（“INBS” 或 “公司”）（納斯達克股票代碼：INBS）今天宣佈，總裁兼首席執行官哈里·西蒙尼迪斯和首席財務官斯皮羅·薩基里斯計劃出席將於2024年4月8日至9日在紐約市舉行的第十四屆LD Micro投資者邀請大會。
LD Micro Invitational XIV Investment Conference
Dates: April 8-9, 2024
Location: Sofitel New York, NYC
Presentation: 12:00 p.m. ET on April 9, 2024
Webcast: https://ldinv14.sequireevents.com/
LD Micro 邀請賽第十四屆投資會議
日期：2024 年 4 月 8 日至 9 日
地點：紐約索菲特酒店
演講：美國東部時間 2024 年 4 月 9 日下午 12:00
網絡直播： https://ldinv14.sequireevents.com/
Management will be available during the event for 1x1 meetings with the investment community. To schedule a meeting please reach out to your LD Micro representative or KCSA Strategic Communications by emailing INBS@kcsa.com.
管理層將在活動期間與投資界進行1x1會議。如需安排會議，請通過電子郵件聯繫您的 LD Micro 代表或 KCSA 戰略通訊 INBS@kcsa.com。
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
關於智能生物解決方案公司
Intelligent Bio Solutions Inc.（納斯達克股票代碼：INBS）是一家提供創新、快速、非侵入性測試解決方案的醫療技術公司。該公司認爲，其智能指紋藥物篩查系統將通過指紋汗液分析徹底改變便攜式測試，這有可能在其他領域得到更廣泛的應用。該測試系統既衛生又具有成本效益，可篩查最近在工作場所使用的常見藥物，包括阿片類藥物、可卡因、甲基苯丙胺和大麻。該技術可在幾秒鐘內收集樣本，在不到十分鐘內得出結果，因此對於安全關鍵行業的僱主而言，這項技術將是一項寶貴的工具。此外，該公司的生物傳感器平台有可能測試多達130種適應症，包括葡萄糖、免疫疾病和傳染病。該公司目前的客戶群包括建築、製造和工程、運輸和物流公司、藥物治療組織和驗屍官。
For more information, visit: http://www.ibs.inc/
欲了解更多信息，請訪問： http://www.ibs.inc/
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
公司聯繫人：
智能生物解決方案公司
info@ibs.inc
領英 | 推特
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
投資者和媒體聯繫人：
瓦爾特·平託，董事總經理
KCSA 戰略傳播
PH: (212) 896-1254
INBS@kcsa.com